巴瑞替尼治疗难治性或重度幼年皮肌炎的长期有效性与安全性
单中心回顾性研究纳入27例对糖皮质激素和免疫抑制剂反应不佳的难治性或重度幼年皮肌炎患儿,加用巴瑞替尼治疗。平均随访25.1个月(范围12至58个月),77%患者皮疹改善、62%完全消退,36个月时70%达到疾病无活动且激素剂量较基线下降,1例因带状疱疹病毒感染住院并暂时停药,无死亡或永久停药。
要点
- 27例难治性或重度幼年皮肌炎患儿加用巴瑞替尼,平均随访25.1个月(范围12至58个月)。
- 36个月随访期间70%(19/27)达到疾病无活动,激素剂量从基线0.50 mg/kg/day降至36个月时0 mg/kg/day(P < 0.001)。
- 1例因带状疱疹病毒感染需住院并暂时停用巴瑞替尼,无死亡或永久停药。
核心结论
- 在36个月随访期内,巴瑞替尼治疗难治性或重度幼年皮肌炎总体显示长期有效且安全。
研究设计与样本
- 单中心回顾性研究,纳入27例对糖皮质激素和免疫抑制剂反应不佳的难治性或重度幼年皮肌炎患儿,接受巴瑞替尼治疗。
主要发现
- 平均随访25.1个月(范围12至58个月),77%(21/27)患者皮疹改善,62%患者皮疹完全消退。
- 12个月时皮肤疾病活动度评分中位数从6.0降至0.8(P < 0.01),CMAS评分从40.5(30.8,45.0)升至52.0(50.0,52.0)(P < 0.05),MMT-8评分从66.0(47.8,72.3)升至79.0(79.0,80.0)(P = 0.004)。
- 36个月随访期间70%(19/27)达到疾病无活动,糖皮质激素剂量从基线0.50(0.34,0.89)mg/kg/day降至36个月时0(0,0.10)mg/kg/day(P < 0.001),三分之一患者(9/27)停用糖皮质激素。
- 疾病无活动率在6、12、24和36个月观察点分别为48.1%(13/27)、70.8%(17/24)、90.0%(18/20)和92.3%(12/13)。
- 影像学分析显示1例钙质沉着改善、2例稳定;3例间质性肺病改善、3例稳定;2例巨噬细胞活化综合征缓解;1例因带状疱疹病毒感染需住院并暂时停用巴瑞替尼,无死亡或永久停药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to evaluate the long-term effectiveness and safety of baricitinib (BAR) add-on therapy for refractory or severe juvenile dermatomyositis (rsJDM) in a practical, real-world setting. METHODS: In this single-centre retrospective study, 27 children with rsJDM and poor response to corticosteroids (CS) and immunosuppressants were treated with BAR. Disease activity was assessed via physician global assessment of overall disease activity (PhyGloVAS), the childhood myositis assessment scale (CMAS), manual muscle testing-8 (MMT-8) and the disease activity score (DAS). Disease response was determined according to the PRINTO criteria at 0, 6, 12, 24 and 36 months after the initiation of BAR treatment. RESULTS: Over an average follow-up period of 25.1 months (ranging from 12 to 58 months), 77% of patients (21 out of 27) experienced improvement in skin rashes, with complete resolution in 62% of patients. Analysis of the median values revealed a significant decrease in the DAS of the skin at 12 months (6.0 vs 0.8, P < 0.01). Furthermore, the CMAS score significantly increased at 12 months (40.5 [30.8, 45.0] vs 52.0 [50.0, 52.0], P < 0.05), and the MMT-8 score also notably increased at 12 months (66.0 [47.8, 72.3] vs 79.0 [79.0, 80.0], P = 0.004) Last observation for the three patients who did not respond was carried forward for their month 12 data. Over the course of the 36-month follow-up, a total of 70% of patients (19 out of 27) achieved inactive disease inactive disease (ID), with a reduction in CS dosage from baseline (0.50 [0.34, 0.89] mg/kg/day) to (0 [0, 0.10] mg/kg/day) at 36 months (P < 0.001). One-third of patients (9 out of 27) discontinued CS treatment. The percentage of patients who achieved ID was 48.1% (13/27), 70.8% (17/24), 90.0% (18/20) and 92.3% (12/13) at the 6-, 12-, 24- and 36-month observation points, respectively. Radiographic analysis revealed an improvement in calcinosis in one patient, while stabilization was observed in two others. Interstitial lung disease improved in three patients and stabilized in three others. Macrophage activation syndrome was resolved in two patients. One patient required hospitalization and temporary cessation of BAR due to herpes zoster virus infection. There were no deaths or anyone who had to permanently discontinue baricitinib due to an adverse event. CONCLUSIONS: We demonstrated the general long-term effectiveness and safety of BAR treatment in patients with rsJDM over a follow-up period of 36 months.
引用
- Wang Z, Lu Y, Qiu X, et al. Long-term effectiveness and safety of baricitinib treatment on refractory or severe juvenile dermatomyositis. Rheumatology (Oxford). 2025. PMID: 40316508. doi:10.1093/rheumatology/keaf225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。